Ultragenyx Pharmaceutical Inc. (RARE) DCF Valuation
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Ultragenyx Pharmaceutical Inc. (RARE) Bundle
Gain insights into your Ultragenyx Pharmaceutical Inc. (RARE) valuation analysis using our sophisticated DCF Calculator! This Excel template comes preloaded with real (RARE) data, allowing you to adjust forecasts and assumptions to accurately determine the intrinsic value of Ultragenyx Pharmaceutical Inc.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 103.7 | 271.0 | 351.4 | 363.3 | 434.2 | 599.9 | 828.7 | 1,144.8 | 1,581.4 | 2,184.6 |
| Revenue Growth, % | 0 | 161.32 | 29.66 | 3.39 | 19.52 | 38.14 | 38.14 | 38.14 | 38.14 | 38.14 |
| EBITDA | -389.8 | -139.8 | -410.3 | -640.5 | -516.5 | -541.8 | -748.4 | -1,033.9 | -1,428.3 | -1,973.0 |
| EBITDA, % | -375.81 | -51.58 | -116.77 | -176.29 | -118.93 | -90.32 | -90.32 | -90.32 | -90.32 | -90.32 |
| Depreciation | 8.5 | 12.3 | 13.2 | 18.2 | 26.0 | 33.0 | 45.6 | 63.0 | 87.0 | 120.3 |
| Depreciation, % | 8.23 | 4.52 | 3.77 | 5.01 | 5.99 | 5.5 | 5.5 | 5.5 | 5.5 | 5.5 |
| EBIT | -398.3 | -152.1 | -423.6 | -658.7 | -542.5 | -547.2 | -755.9 | -1,044.3 | -1,442.6 | -1,992.8 |
| EBIT, % | -384.05 | -56.11 | -120.53 | -181.3 | -124.92 | -91.22 | -91.22 | -91.22 | -91.22 | -91.22 |
| Total Cash | 760.4 | 1,212.0 | 999.1 | 896.7 | 577.2 | 599.9 | 828.7 | 1,144.8 | 1,581.4 | 2,184.6 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 32.8 | 23.1 | 28.4 | 40.4 | 73.4 | 91.6 | 126.5 | 174.7 | 241.4 | 333.4 |
| Account Receivables, % | 31.67 | 8.52 | 8.09 | 11.13 | 16.9 | 15.26 | 15.26 | 15.26 | 15.26 | 15.26 |
| Inventories | 11.5 | 13.0 | 16.2 | 26.8 | 34.0 | 42.9 | 59.3 | 81.9 | 113.1 | 156.2 |
| Inventories, % | 11.13 | 4.81 | 4.62 | 7.37 | 7.82 | 7.15 | 7.15 | 7.15 | 7.15 | 7.15 |
| Accounts Payable | 12.9 | 12.9 | 17.1 | 43.3 | 42.1 | 52.4 | 72.4 | 100.0 | 138.1 | 190.8 |
| Accounts Payable, % | 12.41 | 4.77 | 4.88 | 11.91 | 9.7 | 8.73 | 8.73 | 8.73 | 8.73 | 8.73 |
| Capital Expenditure | -24.8 | -43.9 | -73.1 | -146.1 | -46.8 | -134.3 | -185.5 | -256.3 | -354.0 | -489.0 |
| Capital Expenditure, % | -23.94 | -16.2 | -20.8 | -40.22 | -10.77 | -22.39 | -22.39 | -22.39 | -22.39 | -22.39 |
| Tax Rate, % | 0.29994 | 0.29994 | 0.29994 | 0.29994 | 0.29994 | 0.29994 | 0.29994 | 0.29994 | 0.29994 | 0.29994 |
| EBITAT | -401.6 | -153.1 | -424.5 | -664.1 | -540.8 | -546.9 | -755.5 | -1,043.6 | -1,441.7 | -1,991.6 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -449.4 | -176.4 | -488.7 | -788.4 | -602.9 | -665.0 | -926.7 | -1,280.1 | -1,768.4 | -2,442.9 |
| WACC, % | 9.14 | 9.14 | 9.14 | 9.14 | 9.13 | 9.13 | 9.13 | 9.13 | 9.13 | 9.13 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -5,196.8 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -2,492 | |||||||||
| Terminal Value | -34,925 | |||||||||
| Present Terminal Value | -22,560 | |||||||||
| Enterprise Value | -27,756 | |||||||||
| Net Debt | -170 | |||||||||
| Equity Value | -27,586 | |||||||||
| Diluted Shares Outstanding, MM | 74 | |||||||||
| Equity Value Per Share | -375.10 |
What You Will Receive
- Comprehensive Financial Model: Ultragenyx’s actual data facilitates accurate DCF valuation.
- Complete Forecast Control: Modify revenue growth, profit margins, WACC, and other critical factors.
- Real-Time Calculations: Instant updates allow you to view results as adjustments are made.
- Professional-Grade Template: A polished Excel file crafted for high-quality valuation.
- Flexible and Reusable: Designed for adaptability, enabling ongoing use for in-depth forecasts.
Key Features
- Comprehensive Financial Data: Access reliable historical data and future forecasts specific to Ultragenyx Pharmaceutical Inc. (RARE).
- Adjustable Forecast Parameters: Modify highlighted cells for key metrics such as WACC, growth rates, and profit margins.
- Real-Time Calculations: Automatic updates for DCF, Net Present Value (NPV), and cash flow assessments.
- User-Friendly Dashboard: Intuitive charts and summaries to help visualize your valuation findings.
- Designed for All Levels: An easy-to-navigate structure tailored for investors, financial officers, and consultants.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review Ultragenyx Pharmaceutical Inc.'s pre-filled financial data and forecasts.
- Step 3: Modify key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update in real-time as you adjust your assumptions.
- Step 5: Analyze the results and utilize them for your investment decisions.
Why Choose Ultragenyx Pharmaceutical Inc. (RARE) Calculator?
- Comprehensive Analysis: Incorporates DCF, WACC, and key financial ratios all in one tool.
- Flexible Inputs: Modify the yellow-highlighted cells to explore different financial scenarios.
- In-Depth Evaluations: Automatically computes Ultragenyx’s intrinsic value and Net Present Value.
- Integrated Data: Historical and projected data provide reliable starting points for analysis.
- Expert-Level Quality: Perfect for financial analysts, investors, and pharmaceutical consultants.
Who Should Use This Product?
- Healthcare Investors: Develop comprehensive valuation models for assessing Ultragenyx Pharmaceutical Inc. (RARE) stock.
- Biotech Analysts: Evaluate various valuation scenarios to inform investment strategies in the biotech sector.
- Consultants and Advisors: Deliver precise valuation insights for clients interested in Ultragenyx Pharmaceutical Inc. (RARE).
- Students and Educators: Utilize real-world data to enhance learning in financial modeling and biotech valuation.
- Pharmaceutical Enthusiasts: Gain insights into how companies like Ultragenyx Pharmaceutical Inc. (RARE) are valued within the market.
What the Template Contains
- Preloaded RARE Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.